Picture of Dr. Anna Radomska

Dr. Anna Radomska PhD, MD Faculty, Pathology & Laboratory Medicine

Research Areas

  • Biology of matrix metalloproteinases
  • Matrix metalloproteinases in cancer invasion
  • Role of nitric oxide synthase
  • Regulation of platelet aggregation
  • Role of platelets in carcinogenesis
  • Nanomedicine

About Dr. Anna Radomska

MD - College of Medicine Jagiellonian University (UJ) in Krakow (1978)
Anatomical Pathologist – Department of Pathology UJ (1983)
Histopathologist (equivalent MRC Path) – Department of Pathology UJ (1986)
Honorary Pathology Fellow – King’s College Hospital London UK (1991), University College London UK (1992), St. Bartholomew’s Hospital London UK (1993)
Consultant Pathologist – Department of Pathology UJ (1986-1989), The Coombe Women and Infants University Hospital, Dublin, Ireland (2007-2012), The University Hospital Limerick, Ireland (2014), The University Hospital Galway, Ireland (2014)
Research Associate - Department of Pharmacology University of Alberta (1994-2002), University of Texas in Houston (2002-2005), University of Dublin Trinity College (2006-2007)
PhD (with distinction) – UJ (2016)


Medical and dentistry students – Department of Pathology UJ (1978-1989)
Pathology residents – Department of Pathology UJ (1986-1989), The Coombe Hospital (2007-2012)
Postgraduate teaching – Department of Pharmacology University of Alberta (1994-2002), University of Texas in Houston (2002-2005), University of Dublin Trinity College (2006-2007)

Selected Publications

  • Radomski, A., Sawicki, G., Olson, D.M., Radomski, M.W. The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats. Br. J. Pharmacol. 125:1455-1462(1998)
  • Radomski, A., Stewart, M.J., Jurasz, P., Radomski, M.W. Pharmacological characteristics of solid-phase von Willebrand factor in human platelets. Br.J.Pharmacol.134:1013-1020(2001).
  • Radomski, A., Jurasz, P., Sanders, E.J., Overall, C.R., Biggs, H., Edwards, D., Radomski, M.W. Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br. J. Pharmacol. 137:1330-1338(2002).
  • Radomski, A., Jurasz, P., Alonso-Escolano, D., Drews, M., Morandi, M., Malinski, T. Radomski, M.W. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J.Pharmacol.146:882-893(2005)
  • Medina, C., Santos-Martinez, M.J., Radomski, A., Corrigan, O.I., Radomski, M.W. Nanoparticles: pharmacological and toxicological significance. Br.J.Pharmacol.150:552-555(2007)
  • Li, X., Radomski, A., Corrigan, O.I., Tajber, L., De Sousa Menezes, F., Endter, S., Medina, C., Radomski, M.W. The Platelet Compatibility of Poly(lactide-co-glycolide) (PLGA), Chitosan and PLGA- Chitosan Nanoparticles. Nanomedicine 4:735-746(2009).
  • Radziwon-Balicka, A., Medina, C., O’Driscoll, L., Bazou, D., Inkielewicz-Stepniak, I., Radomski, A.,  Treumann, A., Jow, H., Radomski, M.W. Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. Br. J. Pharmacol. 167:787-804(2012).
  • Radomska, A., Leszczyszyn, J., Radomski, M.W. The nanopharmacology and nanotoxicology of nanomaterials: new opportunities and challenges Adv.Clin.Exp.Med. 25:151-162(2016).